MLYS

NASD Mineralys Therapeutics, Inc.

Nov 5, 2026 · 9:15 AM ET LAST TRADE Market Closed

$17.10 ↑ +0.10 (+0.59%) Trading Up from the previous close of $17.00

YTD change: -52.88%
vs 20-day SMA: -16.24%
vs 200-day SMA: -36.09%

Price ranges

Previous day

$15.53 $17.02

open $16.41 close $17.00

+$0.59 (+3.60%)

Today

$0.00 $0.00

$17.10

Past week

$15.33 $22.48

from $21.38 now $17.10

-$4.28 (-20.02%)

Past month

$15.33 $23.68

from $22.09 now $17.10

-$4.99 (-22.59%)

This year

$15.33 $37.70

from $36.29 now $17.10

-$19.19 (-52.88%)

Price & Performance

-12.28 (-41.94%) / 6M

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Not So Good

The stock is 64.1% away from all-time highs of $47.65
MLYS is down 53% since the beginning of the year
MLYS is down 57% over the past 12 months
MLYS is down 23% over the past 1 month
11% of all MLYS investors are betting against MLYS

MLYS reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is -57.1%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No

EPS $-0.64

Earnings momentum -327.0% Quarterly EPS growth

Quarterly change -327.0%

Valuation

P/E ratio N/A

Enterprise value $876.6M

Beta 0.27

Balance sheet & scale

IncomeN/A

RevenueN/A

Cash$661.4M

Debt$97.6K

Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD

Sector Professional, Scientific, and Technical Services

Industry Group Scientific Research and Development Services

Market cap $1.5B

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Competitor comparison

Ticker	Company	Price	Change
AMGN	Amgen Inc.	$478.48	+3.73%
MRNA	Moderna, Inc.	$258.38	+13.11%
RVMD	Revolution Medicines, Inc.	$199.70	+2.82%
ROIV	Roivant Sciences Ltd.	$38.23	+6.08%
BNTX	BioNTech SE Sponsored ADR	$90.70	+4.35%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.